NCT06736613View on ClinicalTrials.gov

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 11, 2024

Primary Completion Date

December 11, 2027

Study Completion Date

December 11, 2027

Conditions
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaStage III High Grade B-Cell LymphomaStage IV High Grade B-Cell LymphomaDLBCL - Diffuse Large B Cell LymphomaIntravascular Large B-Cell LymphomaDiffuse Large B Cell Lymphoma of BreastDiffuse Large B Cell Lymphoma of TestisHIV-associated Diffuse Large B Cell LymphomaDouble Expressor DLBCL
Interventions
DIAGNOSTIC_TEST

Cerebral Spinal Fluid ctDNA

MSK's Diagnostic Molecular Pathology core has developed and validated a CSF ctDNA assay which has been approved by New York State Department of Health as of 2019

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Rockville Centre

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER